KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Liabilities (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Total Liabilities for 15 consecutive years, with $490.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 8.35% year-over-year to $490.4 million, compared with a TTM value of $490.4 million through Dec 2025, down 8.35%, and an annual FY2025 reading of $490.4 million, down 8.35% over the prior year.
  • Total Liabilities was $490.4 million for Q4 2025 at Travere Therapeutics, up from $465.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $629.7 million in Q4 2022 and bottomed at -$279.8 million in Q3 2023.
  • Average Total Liabilities over 5 years is $499.7 million, with a median of $535.0 million recorded in 2024.
  • The sharpest move saw Total Liabilities crashed 144.72% in 2023, then surged 291.18% in 2024.
  • Year by year, Total Liabilities stood at $474.5 million in 2021, then surged by 32.71% to $629.7 million in 2022, then dropped by 6.61% to $588.1 million in 2023, then fell by 9.02% to $535.0 million in 2024, then dropped by 8.35% to $490.4 million in 2025.
  • Business Quant data shows Total Liabilities for TVTX at $490.4 million in Q4 2025, $465.0 million in Q3 2025, and $522.6 million in Q2 2025.